{"entity":{"id":"nct06395103","kind":"trial","name":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)","aka":["LIGHTBEAM-U01"],"tldr":"A phase 1/2 trial of Zilovertamab vedotin in diffuse large b-cell lymphoma and burkitt lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) is a phase 1/2 interventional study registered as NCT06395103 by Merck Sharp & Dohme LLC, with 90 participants planned, started 2024-08-16 and due to reach its primary completion in 2029-03-31. Interventions recorded: Zilovertamab vedotin. Conditions listed: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06395103","url":"https://clinicaltrials.gov/study/NCT06395103"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl","burkitt-lymphoma","ewing-sarcoma"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["zilovertamab-vedotin"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06395103","phase":"1/2","setting":"LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06395103","source":"https://clinicaltrials.gov/study/NCT06395103","fetchedAt":"2026-10-07T16:54:38.047Z","studySha256":"45bd7b56cdf4c8c63fd4a0495cee71cbdef5223c85c60ab2596e876e44097017","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"6 Months","maximumAge":"25 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":90,"enrolmentType":"ESTIMATED","siteCount":71,"recruitingSiteCount":70,"countries":["Australia","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Netherlands","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-08-16","startedType":"actual","enrolled":90,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06395103/","neighbours":{"cancer":[{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}